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Abstract
Background and aims: Small bowel capsule endoscopy (SBCE) may detect proximal small bowel
lesions that have been previously missed by ileocolonoscopy and small bowel imaging in patients
with known ileal and/or colonic Crohn's disease (CD). We aimed to evaluate whether the
therapeutic management is influenced by SBCE findings.
Methods: Retrospective single center study. Inclusion of consecutive patients with known
non-stricturing and non-penetrating ileal and/or colonic CD, submitted to SBCE to evaluate
disease extension and activity, with ≥ 1 year follow-up. Lesions were classified with the Lewis
score (LS) as non-significant (LS b 135), mild (135 ≤ LS ≤ 790), or moderate-to-severe (LS N 790).
Therapeutic changes were assessed three months after SBCE.
Results: Fifty consecutive patients (35 ± 13 years, 52% females) were included. At
ileocolonoscopy, disease location was ileal (L1) in 60%, colonic (L2) in 10% and ileocolonic (L3)
in 30% of the patients. In 33 patients (66%) SBCE detected significant proximal lesions previously
missed by other modalities. The proportion of patients on thiopurines and/or biologics before
SBCE was 2/50 (4%); this was significantly higher three months after SBCE, 15/50 (30%), p = 0.023.
Treatment with thiopurines and/or biologics was started more often in patients with proximal
small bowel lesions [13/33 (39%) vs. 1/17 (6%), p = 0.011, relative risk (RR) 6.5], particularly
when severe (6%, 36% and 45% of patients with non-significant, mild and moderate-to-severe
inflammation, respectively).
Conclusions: SBCE diagnoses previously undetected lesions and it influences therapeutic
management of CD, triggering an earlier introduction of immunomodulators and/or biological
therapy.
© 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.utileiros, Creixomil, 4835-044,
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Crohn's disease (CD) is a chronic idiopathic inflammatory
bowel disease that may affect any segment of the digestive
tract and often involves the small bowel.1 Ileocolonoscopy
remains the first endoscopic procedure to establish the
diagnosis in patients with suspected CD. Irrespective of the
findings at ileocolonoscopy, further investigation is advis-
able to determine the location and extent of CD in the upper
gastrointestinal tract and the small bowel.1 The evaluation
of the small bowel often relies on cross-sectional imaging with
magnetic resonance enterography (MRE) or computed tomog-
raphy enterography (CTE), for the assessment of the transmural
nature of the disease and its anatomical distribution, charac-
terization of strictures and detection of extraluminal disease. In
this setting, the role of small bowel capsule endoscopy (SBCE) is
still evolving.2 SBCE has been shown to improve the detection
of proximal small bowel lesions when compared to both CTE
and MRE, while the diagnostic yield seems to be equivalent
when lesions are limited to the terminal ileum.3,4 The clinical
implications of this incremental yield, mainly for mild proximal
lesions, in patients with known CD remain to be clarified,
although it is currently recognized that the finding of extensive
and/or proximal lesions may influence therapeutic decisions
towards an earlier introduction of immunomodulators and/
or biological therapy, with the aim of reducing long term
complications and disabling disease.5–7 Nonetheless, data
regarding the impact of SBCE findings on therapeutic decisions
are scarce,8,9 and the burden of proximal lesions in patients
with known CD has not been extensively investigated.
The aim of this study was to determinewhether new lesions
detected by SBCE in the proximal small bowel and/or not
previously recognized at the index ileocolonoscopy influenced
the therapeutic management of patients with known ileal
and/or colonic CD.
2. Methods
We conducted a single center retrospective study, from
January 2008 to December 2012, with an inclusion of
consecutive patients with established non-stricturing and
non-penetrating ileal and/or colonic CD, submitted to SBCE
to assess disease extent and activity. All patients had an
ileocolonoscopy as the first endoscopic diagnostic proce-
dure. Patients with unsuccessful ileoscopy at colonoscopy
were not included in this study. Patients with obstructive
symptoms and/or those with evidence of ileal stenosis at
ileocolonoscopy and/or radiological features of stricturing
or penetrating disease did not undergo subsequent SBCE.
Small bowel radiological imaging was not mandatory prior to
SBCE. Thus, patients with no clinical features of stricturing
or penetrating disease and no stricture at the index
ileocolonoscopy were allowed to undergo SBCE without
previous small bowel imaging. Patients taking aspirin or
nonsteroidal anti-inflammatory drugs discontinued the medi-
cation at least four weeks before the SBCE. Baseline variables
assessed at the time of SBCE included age, Montreal classifi-
cation, serum inflammatory biomarkers, history of abdominal
surgery related to Crohn's disease and current medication. All
patients followed a clear liquid diet for 24 h and 12 h fasting
prior to SBCE (PillCam® SB2, Given® Imaging Ltd Yoqneam,Please cite this article as: Cotter J, et al, Tailoring Crohn's disease treatm
(2014), http://dx.doi.org/10.1016/j.crohns.2014.02.018Israel). All SBCE were reviewed by two experienced physicians
(N200 SBCE examinations) using RAPID Reader®, and in case of
no interobserver agreement the findings were reviewed until a
consensus report was achieved. Small bowel inflammatory
activity was systematically assessed with the Lewis score10
(LS) for each tertile of the small bowel, using the calculator
included in the RAPID® software. The length of each tertilewas
determined by equally dividing the small bowel transit time of
the capsule in three parts. Following a widely accepted
methodology,10 a LS b135 was assumed to correspond to
normal examination or clinical insignificant lesions, a LS of 135
to 790 corresponded to mild inflammatory activity, and a
LS N790 corresponded to moderate or severe inflammatory
activity. Small bowel lesions were considered to have proximal
location if they were located in the upper two thirds of the
small bowel (first two tertiles of the SBCE) and/or located in
the third tertile proximal to the terminal ileum, out of the
reach of the colonoscope. For the purpose of the study, the
terminal ileumwas considered to correspond to the last 10 min
of the passage of the capsule in the small bowel before
entering the cecum, which translates to a length of approxi-
mately 15 cm, assuming an average velocity of 1.5 cm/min for
the passage of the capsule, as described elsewhere.11 In those
cases where the capsule did not reach the cecum, small bowel
tertiles were determined based on the last small bowel image
available; in those cases, the relative position of the capsule to
the ileocecal valve was estimated using topographic landmarks
with the localization track of RAPID® software, as well as the
estimated distance from the duodenum at the time of battery
exhaustion. Any changes in CDmedication within threemonths
after the SBCE were assessed.
Statistical analysis was performed using SPSS version 16.0
(SPSS Inc., Chicago, Illinois). Baseline and SBCE data were
summarized using descriptive statistics. Categorical data
were analyzed with Pearson's chi-squared or Fisher's exact
test. Univariate and multivariate logistic regression analyses
were performed considering the start of thiopurines and/or
biologics within three months of the SBCE as the dependent
variable. A p-value b0.05 was considered statistically
significant.3. Results
Fifty consecutive patients (mean age 35 ± 13 years, 52%
females) with known non-stricturing and non-penetrating
ileal and/or colonic CD, submitted to SBCE to assess disease
extent and activity, were included in the study. Baseline
characteristics, interventions and outcomes of the popula-
tion are summarized in Table 1. SBCE was performed shortly
after (less than 3 months) the diagnosis of CD in 70% of
patients (n = 35) and within the first year after the initial
diagnosis in 84% (n = 42). The location of the disease at the
index ileocolonoscopy was ileal (L1) in 60% (n = 30), colonic
(L2) in 10% (n = 5) and ileocolonic in 30% (n = 15) of patients.
Seven patients (14%) had perianal fistulae and/or abscesses.
Seven patients (14%) had previous history of abdominal
surgery related to CD. Small bowel imaging was performed in
32 patients (64%), either with CT enterography/enteroclysis
(n = 13), CT with no oral contrast intake (n = 10), MR
enterography (n = 4) or small bowel follow through (n = 5).
Small bowel imaging was unremarkable in 56% (n = 18) andent: The impact of small bowel capsule endoscopy, J Crohns Colitis
Table 1 Population baseline characteristics, interventions
and outcomes.
Age 35 ± 13 years
Gender (% female) 52% females
CD location
Ileal (L1) 60% (n = 30)
Colonic (L2) 10% (n = 5)
Ileocolonic (L3) 30% (n = 15)
Complex perianal disease 14% (n = 7)
Abdominal surgery related to CD 14% (n = 7)
Patients with anemia and/or raised
inflammatory biomarkers at the time of SBCE
58% (n = 29)
Small bowel imaging 64% (n = 32)
Time from diagnosis to SBCE (months)
Within 3 months 70% (n = 35)
Within 1 year 84% (n = 42)
Proximal small bowel lesions on SBCE
(SL ≥ 135)
66% (n = 33)
Proximal moderate-to-severe inflammation
on SBCE (SL N 790)
22% (n = 11)
Patients on thiopurines and/or biologics at
the time of SBCE (%)
4% (n = 2)
Patients on thiopurines and/or biologics
within 3 months after SBCE (%)
30% (n = 15)
Mean follow-up after SBCE (years) 2.9 ± 1.3
[1–5] years
3Impact of capsule endoscopy in Crohn's diseaserevealed features of ileitis in 44% (n = 14) of patients. In one
patient, CT additionally identified features of non-stricturing
CD of the upper jejunum. Upper endoscopy was performed in
66% of patients (n = 33), revealing no features of CD in any of
the patients. At the time of SBCE, patients were medicated
with aminosalicylates (32%, n = 16), budesonide (36%, n = 18),
oral prednisone (10%, n = 5), thiopurines (2%, n = 1) or
biological therapy (2%, n = 1); nine patients (18%) had not
initiated any medication. Twenty-nine patients (58%) had
raised inflammatory biomarkers (C-reactive protein, erythro-
cyte sedimentation rate, ferritin, platelet count) and/or
anemia at the time of capsule endoscopy. The rate of complete
examinations, with the capsule reaching the cecum within
the battery life, was 80% (n = 40). Overall, SBCE detected
significant lesions (LS ≥ 135) in 84% of patients (n = 42), being
mild (135 ≤ LS ≤ 790) in 44% (n = 22) and moderate to severe
(LS N 790) in 40% (n = 20). In thirty-seven patients (74%) the
capsule detected lesions in the terminal ileum, which had
already been identified at index ileocolonoscopy. In patients
with colonic disease (L2), SBCE detected previously unsuspect-
ed inflammatory activity of the terminal ileum in 3/5 (60%),
that had not been detected at ileocolonoscopy. In 8 patients
(16%) with ileal involvement at index ileocolonoscopy, lesions
were not detected by the SBCE, although proximal lesions were
identified in 2 of those patients. Overall, thirty-three patients
(66%) had significant inflammatory activity in the small bowel
proximal to the level reached by the colonoscope, and in 22%
(n = 11) it was moderate or severe. These lesions had not been
previously recognized at the index ileocolonoscopy or small
bowel radiological imaging in all but one patient in whom small
bowel CT scan identified jejunal disease.
Three months after the SBCE, patients' medication includ-
ed aminosalicylates (22%, n = 11), budesonide (36%, n = 18),Please cite this article as: Cotter J, et al, Tailoring Crohn's disease treatm
(2014), http://dx.doi.org/10.1016/j.crohns.2014.02.018thiopurines (18%, n = 9), or biological therapy (12%, n = 6);
three patients (6%) remained without anymedication— Fig. 1.
Overall, 44% of patients (n = 22) initiated a new IBD treatment
within three months after the SBCE, as follows: 5 patients
(10%) were started on budesonide, 9 patients (18%) started
immunosuppression with thiopurines, 5 patients (10%) started
biological therapy and 3 patients (6%) underwent surgery. The
introduction of thiopurines and/or biologics occurred in 2/9
(22%) patients who were not taking any medication, 2/16
(13%) patients on aminosalicylates, 5/18 (28%) patients taking
budesonide and 4/5 (80%) patients on prednisone at the time
of SBCE. One other patient was escalated from azathioprine to
infliximab. Patients were medicated with thiopurines and/or
infliximab in 2/50 (4%) and 15/50 (30%) at the time of SBCE
and three months after the SBCE, respectively (p = 0.023).
Regarding baseline serum analysis, thiopurines and/or bio-
logics were initiated in 8/29 (27.6%) patients with anemia
and/or raised inflammatory biomarkers vs. 6/21 (28.6%) of
patients who had normal serum analysis at the time on SBCE
(p = 0.593). The start of treatment with thiopurines and/or
biologics in patients who were previously naïve to those
medications occurred in 13/33 (39%) vs. 1/17 (6%) patients
with or without significant inflammatory activity in the
proximal small bowel detected at the SBCE, respectively
(p = 0.011). Additionally, there was a trend towards starting
thiopurines and/or biologics when proximal small bowel
lesions were more severe, occurring in 1/17 (6%), 8/22 (36%)
and 5/11 (45%) of patients with non-significant, mild and
moderate to severe proximal lesions, respectively— Fig. 2. On
multivariate logistic regression, proximal involvement with
significant inflammatory activity (LS ≥ 135) on SBCE was
independently associated with the start of thiopurines and/
or biologics, with a RR (relative risk) of 6.5 (p = 0.029). The
other variables included in the multivariate logistic regression
were not associated with such a therapeutic adjustment:
anemia and/or raised serum analysis (p = 0.733), ileal
involvement at the index ileocolonoscopy (p = 0.969), com-
plex perianal disease (p = 0.194) or prior abdominal surgery
(p = 0.817). The mean follow-up after SBCE was 2.9 ± 1.3 [1–
5] years. The proportion of patients in corticosteroid-free
remission at follow-up was 57.1% (8/14) in the immunosup-
pression group versus 61.1% (22/36) among patients who were
not taking immunomodulators or biological therapy (p =
0.552).4. Discussion
In patients with CD, the location and extent of the disease in
the upper gastrointestinal tract and the small bowel should be
assessed at diagnosis in order to establish the prognosis and
define the therapeutic strategy.1 In a recent meta-analysis,12
SBCE was superior to push enteroscopy, small bowel follow
through and CTE, but not to MRE, in the evaluation of patients
with nonstricturing small bowel CD. SBCE has been shown to
detect proximal small bowel lesions in up to 50% of patients
with previously diagnosed ileal CD.13 It has also been shown to
improve the detection of proximal small bowel lesions when
compared to both CTE and MRE, while the diagnostic yield
seems to be equivalent when lesions are limited to the
terminal ileum.3,4 The clinical implications of this incremental
yield is uncertain, although the finding of extensive and/orent: The impact of small bowel capsule endoscopy, J Crohns Colitis
Figure 1 Baseline and post-SBCE medications for Crohn's disease.
4 J. Cotter et al.proximal lesions have been considered to potentially trigger
an earlier introduction of immunomodulators and/or biolog-
ical therapy, with the aim of reducing long term complications
of the disease5–7; this possibility was demonstrated herein. In
a recent retrospective study of 108 patients, with a median
follow-up of 24 months, including 32 patients with ileal
disease, 25 patients with colonic disease, and 51 patients
with ileocolonic disease, jejunal lesions at SBCE were
detected in 56% of patients, mainly in those who also
presented ileal involvement. The presence of jejunal lesions
was the only independent factor significantly associated with
an increased risk of relapse and could be regarded as a factor
of severity.14 Also in a large series of 1403 Korean patients
with CD, jejunal involvement was independently associated
with worse long-term prognosis, higher use of corticosteroids
and thiopurines, and higher rates of strictureplasties and
hospitalizations.15 In 2011, Long et al.9 reported a high rate of
positive SBCE studies among CD patients, with only 22.2% of
patients having normal examinations, and 47.6% presenting
with severe mucosal inflammation. Our results are consistent
with these data, reinforcing the importance of accurately
establishing the extent and severity of CD. In our study, SBCE
detected significant inflammatory activity (LS ≥ 135) in the
vast majority of patients (84%), being mild (135 ≤ LS ≤ 790)
in 44% andmoderate to severe (LS N 790) in 40% of cases. Rosa
et al.16 recently demonstrated that the use of the Lewis score
to characterize and grade the inflammatory activity on SBCEFigure 2 Start of thiopurines and/or biologics according to the d
Please cite this article as: Cotter J, et al, Tailoring Crohn's disease treatm
(2014), http://dx.doi.org/10.1016/j.crohns.2014.02.018may contribute to an earlier and more accurate diagnosis of
CD. Also in this study, the Lewis score was useful to objectively
grade and quantify small bowel inflammatory activity, and it
was associated with the likelihood of escalating therapy after
a follow-up of three months after the SBCE. The capsule
detected significant inflammatory activity in the proximal
small bowel, which had not been previously recognized either
at ileocolonoscopy or small bowel imaging, in 66% of patients.
Treatment with thiopurines and/or biologics was initiated
more often in patients with significant inflammatory activity
in the proximal small bowel (39% vs. 6%, p = 0.011).
Additionally, we observed a trend towards starting immu-
nosuppression and/or biologics when proximal small bowel
lesions were more severe. In most cases, SBCE were
requested by the attending GE physician shortly after the
diagnosis of CD by ileocolonoscopy, with the aim of assessing
disease extent and activity, as the finding of extensive small
bowel disease has been increasingly regarded as a marker of
severity and poorer outcomes in CD, which should trigger
treatment escalation according to current recommendations.7
From a practical point of view, physicians regarded the
capsule information as crucial for treatment decision. As
detailed above, thiopurines and/or biologics were initiated in
27.6% of patients with anemia and/or raised inflammatory
biomarkers and in 28.6% of those with normal serum analysis
(p = 0.593) at the time of SBCE, suggesting that serum analysis
was not the key factor triggering treatment escalation.egree of proximal inflammatory activity at SBCE (Lewis score).
ent: The impact of small bowel capsule endoscopy, J Crohns Colitis
5Impact of capsule endoscopy in Crohn's diseaseConversely, on logistic regression, proximal involvement with
significant inflammatory activity (LS ≥ 135) on SBCE was
independently associated with the start of thiopurines and/
or biologics, with a RR (relative risk) of 6.5 (p = 0.029).
The fact that a slightly larger proportion of patients not
taking immunosuppressive therapy was doing better at
follow-up (61.1% vs. 57.1% in corticosteroid-free remission,
p = 0.552) is likely related to the fact that these patients had
less severe disease from the beginning. As the methodology of
our study did not contemplate an arm of patients with
extensive small bowel involvement not being submitted to
immunosuppression, we cannot extrapolate from our results
that the therapeutic intervention that was triggered by the
findings on capsule endoscopy resulted in an improved
prognosis, however we can assume that it induced therapeutic
escalation, which, based on data from the literature, can be
expected to reduce the likelihood of clinical relapse and
hospitalizations.
From another perspective, there is ongoing discussion on
whether SBCE could be used to guide the decision of
stopping drugs such as thiopurines and/or biologics when
mucosal healing is documented.5,6,17,18 In our study, none of
the patients had a therapeutic downgrade based on SBCE
findings, which could be explained by the fact that, at the
time of SBCE, few patients were medicated with thiopurines
and/or biological therapy, presumably because the staging
of disease extension had not been concluded, or it had
been performed with less sensitive small bowel radiological
imaging. However, we should acknowledge the fact that only
32/50 patients (64%) were submitted to small bowel imaging
prior to SBCE, including the use of small bowel follow through or
CT scan with no oral contrast intake, less accurate than CT/MR
enterography, which was performed in 34% of patients (n = 17).
This could have eventually precluded the recognition of some
of the lesions that in our study were only detected by the
SBCE.
Regarding the risk of capsule retention, this has been
shown to be increased in patients with known CD, particu-
larly when there is a history of obstructive symptoms or
known intestinal stenosis.19–23 Cross-sectional imaging or
Agile® patency capsule seem to be equally effective in
identifying stenoses that may cause capsule retention.24,25
In our hospital, we do not systematically use Agile® patency
capsule, and during this study we did not perform small
bowel imaging in all patients with known CD prior to SBCE,
except for those with obstructive symptoms or known
intestinal stenosis. Although capsule retention rate was
relatively low (6%) when compared to data reported in the
literature,18 these patients developed obstructive symptoms
and finally underwent abdominal surgery to retrieve the
capsule and treat underlying disease, after unsuccessful
medical management and attempt of endoscopic removal.
All patients who had capsule retention had been submitted
to small bowel cross-sectional imaging that did not identify
any stenoses and had no previous history of obstructive
symptoms.
To conclude, the role of SBCE in the evaluation of patients
with known CD is still evolving, however there is growing
evidence that it may significantly improve the detection of
lesions within the small bowel. It may potentially contribute
to influence therapeutic management, towards an earlier
introduction of immunomodulators and/or biological therapy,Please cite this article as: Cotter J, et al, Tailoring Crohn's disease treatm
(2014), http://dx.doi.org/10.1016/j.crohns.2014.02.018particularly in patients with moderate to severe inflammatory
activity in the proximal small bowel. Whether this approach
will improve outcomes in CDwill require further investigation.
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